熱門資訊> 正文
诺和诺德、罗氏获得汇丰银行升级
2025-10-02 04:12
- 諾和諾德(NVO) 0
- 團車網(TC) 0
- 羅氏(ADR)(RHHBY) 0
- HSBC has upgraded both Novo Nordisk (NVO) and Roche (OTCQX:RHHBY) to buy from hold.
- Analyst Rajesh Kumar noted that Novo is focusing more on reimbursed medical and direct-to-consumer channels. He added that the Danish pharma's pipeline deserves more appreciation. It's “quite difficult to argue that Novo’s next generation portfolio is sub-optimal compared with Lilly’s (LLY) portfolio, especially after the clinical readouts from orforglipron trials, as well as oral semaglutide."
- Kumar also said that 2026 data readouts for REDEFINE4, which is examining CagriSema against Lilly's weight loss drug Zepbound (tirzepatide) and the EVOKE trial testing oral semaglutide (the active ingredient in Wegovy) for Alzheimer's disease could provide a nice risk/reward.
- For Roche, Kumar believes that Street consensus of revenue growth "is 100-200bp below its own internal assessment of revenue opportunity."
- Roche also has obesity candidates in development, which, he added, "might drive the Street to a medium-term revenue growth upgrade cycle."
More on Novo Nordisk, Roche
- The Truth About Novo Nordisk: 4 Myths That Don't Hold Up
- Novo Nordisk: Wegovy Sales Soar, Trump Tariffs No Threat
- Roche's Giredestrant: A Ray Of Hope On A Cloudy Horizon?
- CVS PBM Caremark exploring $200 copay for Novo Nordisk's Wegovy - report
- Pfizer – U.S. drug pricing deal boosts EU drugmakers
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
